DA Davidson Issues Pessimistic Forecast for USNA Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Research analysts at DA Davidson reduced their FY2024 earnings per share estimates for USANA Health Sciences in a report released on Wednesday, October 23rd. DA Davidson analyst L. Weiser now anticipates that the company will earn $2.45 per share for the year, down from their previous forecast of $2.51. DA Davidson has a “Neutral” rating and a $35.00 price objective on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.50 per share. DA Davidson also issued estimates for USANA Health Sciences’ FY2025 earnings at $2.23 EPS.

Separately, StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

USANA Health Sciences Trading Up 6.1 %

Shares of USANA Health Sciences stock opened at $36.58 on Thursday. The business’s 50 day simple moving average is $37.98 and its 200-day simple moving average is $42.55. The stock has a market capitalization of $696.85 million, a price-to-earnings ratio of 12.93, a PEG ratio of 1.15 and a beta of 0.89. USANA Health Sciences has a twelve month low of $34.15 and a twelve month high of $55.45.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million for the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a return on equity of 10.80% and a net margin of 6.30%. During the same period in the prior year, the firm earned $0.59 EPS.

Insider Buying and Selling

In related news, Director Gilbert A. Fuller sold 674 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Gilbert A. Fuller sold 674 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Insiders sold 7,940 shares of company stock valued at $311,670 in the last three months. 0.33% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in USNA. DGS Capital Management LLC boosted its stake in USANA Health Sciences by 61.8% during the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock valued at $352,000 after purchasing an additional 2,773 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in USANA Health Sciences by 18.1% during the 1st quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock valued at $1,883,000 after purchasing an additional 5,952 shares in the last quarter. Pzena Investment Management LLC boosted its stake in USANA Health Sciences by 3.1% during the 1st quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock valued at $38,089,000 after purchasing an additional 23,729 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in USANA Health Sciences by 22.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock valued at $409,000 after purchasing an additional 1,560 shares in the last quarter. Finally, BOKF NA boosted its stake in USANA Health Sciences by 274.5% during the 1st quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after purchasing an additional 2,031 shares in the last quarter. 54.25% of the stock is owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.